This invention is concerned with compounds of the formula wherein A,
R.sup.1 to R.sup.5 are as defined in the specification and G is a
pyridine, quinoline or pyrimidine group as defined in the specification,
and pharmaceutically acceptable salts thereof. The invention further
relates to pharmaceutical compositions containing such compounds, to a
process for their preparation and to their use for the treatment and/or
prevention of diseases which are associated with the modulation of SST
receptors subtype 5.